Articles Vol. 66 No. 1 07/01/2025

6. EVALUATION OF TREATMENT OUTCOMES FOR ORAL CANDIDIASIS IN HIV/AIDS PATIENTS AT THE CENTER FOR TROPICAL DISEASES, NGHE AN GENERAL FRIENDSHIP HOSPITAL (2022-2024)

Ngu Thi Tham1,2, Vu Van Du3,4, Que Anh Tram5,6
1 Thai Thuong Hoang Hospital
2 Bệnh viện Thái Thượng Hoàng
3 National Hospital of Obstetrics and Gynecology
4 Bệnh viện Phụ sản Trung ương
5 Nghe An Friendship General Hospital
6 Bệnh viện Hữu nghị Đa khoa Nghệ An
Corresponding author: ngutham93@gmail.com
DOI: 10.52163/yhc.v66i1.1903
18 Views
18 Downloads
Keywords
HIV/AIDS fungi oral
Abstract

Objectives: The study aimed to evaluate the treatment outcomes for oral candidiasis in HIV/ AIDS patients at the Center for Tropical Diseases, Nghe An Friendship General Hospital.

Methods: Non-randomized, non-controlled intervention study was employed.

Results: 78.6% of the clinical lesions were gone after 4 weeks. Fungal testing showed negative results after 4 weeks as 78.6%. The negative HIV viral load before and after treatment for oral candidiasis increased from 11.9% to 35.7%, p < 0.05. The positive HIV viral load decreased significantly from 61.5% to 38.5%, p < 0.05. The failure rate after 4 weeks of treatment for oral candidiasis was 15.4%(6/39), of which the treatment failure in HIV/AIDS patients of the stages III and IV was 44.4% and 100.0%, respectively. The rate of adverse effects of fluconazole150mg was 11.4% (9/42). The most common adverse effects included nausea (16.7% (7/42), diarrhea (9.5%), abdominal pain (4.8%), and flatulence (4.8%), which were naturally gone after stopping treatment 1-3 days.

Conclusions: The cure rate of oral candidiasis with fluconazole 150mg was 84.6%(33/39). The rate of adverse effects was 11.4% (9/42). The most common adverse effect was nausea 16.7% (7/42), which was gone 1-3 days after stopping treatment.

References
[1]
Hodgson TA, Greenspan D, Greenspan JS (2004). Oral lesions of HIV disease in industrialized countries. Proceedings of the 5th World Workshop on Oral Health and disease in AIDS, July 6-9, 2004, Phuket, Thailand. Advances in Dental Research 2005. Google Scholar
[2]
Tarun Kumar and Neha Arora et al. (2023). Candidiasis lesions in oral cavity in immune compromised HIV positive patients: A review of Literature: https://doi.org/10.33545/26649659.2023.v5.i1a.4. Google Scholar
[3]
Maeve M. Coogan end et al (2005). Oral lesions in infection with human immunodeficiency virus. Google Scholar
[4]
Silvere D Zaongo et al. (2023), Candida albicans can foster gut dysbiosis and systemic inflammation during HIV infection. HIV/AIDS (Auckl).14:15:683-696 https://doi.org/10.1080/19490976.2167171 Google Scholar
[5]
Nguyễn Ngọc Thiên Hương và CS (2007), Những tổn thương niêm mạc miệng liên quan với nhiễm HIV ở người cai nghiện ma túy, Tạp chí Y học Tp. Hồ Chí Minh. Tập11(2), Tr.200-205 Google Scholar
[6]
Patton LL, Bonito AJ, Shugars DAA systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2001, vol. 92(pg. 170-9) Google Scholar
[7]
BaccagliniL, Atkinson JC, PattonLL, et al. Management of oral lesions in HIV-positive patients, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2007, vol. 103 Suppl 50(pg. e1-23) Google Scholar
[8]
Graybill JR, Vazquez J, Darouiche RO, et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients, Am J Med, 1998, vol. 104 (pg. 33-9) Google Scholar
[9]
Omar Jm Hamza et al. Single-Dose Fluconazole versus Standard 2-Week Therapy for Oropharyngeal Candidiasis in HIV-Infected Patients: A Randomized, Double-Blind, Double-Dummy Trial. Clinical Infectious Diseases, Volume 47, Issue 10, 15 November 2008, Pages 1270–1276. Google Scholar